首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1863598

全球 SYK 抑制劑市場：價格、銷售及臨床試驗展望（2030 年）

Global SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook 2030

出版日期: 2025年11月01日 | 出版商:

KuicK Research | 英文 110 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球 SYK 抑制劑市場：價格、銷售及臨床試驗展望 2030 年報告的主要發現與亮點：

全球 SYK 抑制劑市場成長（2020-2024 年）：複合年增長率 13%
已核准的 SYK 抑制劑藥物：1 種
已獲批准藥物的劑量、價格和銷售分析
全球市場趨勢、規模與未來機會展望
全球 SYK 抑制劑臨床研發管線概況：超過 15 種藥物
按公司、適應症和研發階段劃分的全球 SYK 抑制劑臨床研發管線
競爭格局

SYK 抑制劑的需求及其重要性報告

SYK抑制劑市場正在快速發展，SYK酶標靶在調節免疫反應和發炎中的作用已被廣泛認可。 SYK抑制劑已成為一種極具前景的新型治療藥物，尤其是在自體免疫疾病、血液系統疾病和癌症的治療方面。本報告詳細概述了SYK抑制劑的現狀，追蹤了近期科學進展、臨床試驗和未來的商業機會。隨著標靶免疫療法的興起，SYK抑制劑有望滿足迫切的未滿足醫療需求，這使得該治療領域對投資者、研究人員和臨床醫生日益重要。

本報告包含的臨床研究和試驗洞察

本報告全面深入分析了正在進行的SYK抑制劑臨床研究。目前有多項臨床試驗正在進行中，其中大多數針對類風濕性關節炎、特發性血小板減少性紫斑症（ITP）和系統性紅斑狼瘡（SLE）等自體免疫疾病。在這些疾病中，SYK在免疫細胞活化和發炎中發揮關鍵作用。此外，SYK抑制劑在癌症臨床試驗中正蓬勃發展，目前正被探索用於治療血液系統惡性腫瘤和實體腫瘤。

其他正在進行的試驗包括使用新型候選藥物（如索維普利尼）和其他實驗性藥物的試驗。同時，其他藥物，包括第一個核准的SYK抑制劑福斯他替尼（Tavarisse），也在正在進行的試驗中進行評估。這些試驗包括評估將SYK抑制劑與其他療法（如JAK抑制劑和化療）合併使用，以改善癌症等疾病的療效並降低抗藥性的試驗。這些試驗表明，從北美、歐洲和亞洲等全球視角來看，人們對SYK抑制的臨床潛力越來越感興趣。因此，本節將為利害關係人提供寶貴的資源，幫助他們深入了解這些抑制劑的治療潛力和地理覆蓋範圍。

參與 SYK 抑制劑研發的主要公司

越來越多的製藥和生技公司正積極參與 SYK 抑制劑的研發。 Rigel Pharmaceuticals 及其上市產品 fostamatinib 仍然是該領域的主要參與者，其他公司也在該領域穩步推進。 Hutchmed 的 sobreprenib (HMPL-523) 目前正處於後期臨床試驗階段，是最有希望的候選藥物之一，尤其適用於治療 ITP（特發性血小板減少性紫斑症）。該藥物已獲得突破性療法認定，進一步支持其解決免疫性血小板減少症領域未滿足醫療需求的潛力。

其他正在開發 SYK 抑制劑的公司包括 Gilead Sciences 等大型製藥公司以及 Ignota Labs 和 Arcus Biosciences 等規模較小的生物技術公司。這些公司的目標適應症範圍廣泛，從自體免疫疾病到癌症。許多此類藥物正以聯合療法的形式進行測試，以提高緩解率並克服治療抗藥性等挑戰。隨著SYK抑制劑市場競爭格局的不斷擴大，合作和授權授權正日益用於推進臨床研究並加速產品上市。

SYK/TIGIT抑制劑領域未來趨勢報告

由於越來越多的藥物進入臨床研發管線以及新適應症的探索，SYK抑制劑領域預計未來將迎來顯著成長。首個SYK抑制劑福斯他替尼（fostamatinib）已獲準用於治療特發性血小板減少性紫斑症（ITP），該類藥物正逐漸獲得認可，其在腫瘤學和自體免疫疾病治療的潛力也日益凸顯。 SYK抑制劑能夠針對關鍵免疫細胞通路，使其成為治療選擇有限的疾病（例如慢性淋巴性白血病和類風濕性關節炎）的理想選擇。

隨著新的臨床數據不斷湧現，將SYK抑制劑與其他免疫療法（例如PD-1/PD-L1抑制劑）或傳統化療合併使用，有望開啟更多治療可能性。此外，預測SYK抑制療效的生物標記研究進展，可望實現個人化治療。這一趨勢預計將推動下一代SYK抑制劑的研發，這些抑制劑有望成為自體免疫疾病、血液系統疾病以及腫瘤治療的基礎。 SYK抑制劑市場預計將快速成長，FDA和EMA等監管機構已對某些候選藥物提供優先審查。展望未來，隨著臨床試驗的進展和新藥獲批，SYK抑制劑對患者護理和整體醫療保健格局的影響將持續擴大，為患者帶來希望，並為醫療保健和生物製藥行業的利益相關者創造新的機會。

Global SYK Inhibitor market Growth 2020 - 2024: 13% CAGR
Approved SYK inhibitor Drugs: 1
Dosage, Price & Sales Insight Of Approved Drug
Global Market Trend, Size & Future Opportunity Outlook
Comprehensive Insight On Global SYK Inhibitors Clinical Pipeline: > 15 Drugs
Global SYK Inhibitors Clinical Pipeline By Company, Indication & Phase
Competitive Landscape

SYK Inhibitors Need & Why This Report?

The SYK inhibitors market is rapidly developing, with growing recognition of the enzyme target, SYK, in immune response and inflammation regulation. SYK inhibitors have become an encouraging new therapeutic class, especially in the treatment of autoimmune diseases, hematological conditions, and cancer. This report describes in detail the landscape of SYK inhibitors, tracking recent scientific advances, clinical trials, and future commercial opportunities. With targeted immune therapies on the rise, SYK inhibitors are in a position to help with pressing unmet medical needs, making this class increasingly important to investors, researchers, and clinicians.

Clinical Studies & Trials Insight Included In Report

The report gives comprehensive insight into the currently ongoing clinical studies of SYK inhibitors. At present, multiple clinical trials are going on; the majority of them are on autoimmune diseases such as rheumatoid arthritis, ITP, and SLE, where SYK plays a crucial role in the activation of immune cells and inflammation. Besides, trials on cancer are also gaining momentum as SYK inhibitors are being considered for hematological malignancies and solid tumors.

Some other ongoing trials involve emerging candidates, such as Sovleplenib and other experimental drugs, while others, including the first approved SYK inhibitor, fostamatinib (Tavalisse), are still being evaluated in active trials. Of these, some evaluate the efficacy of combining SYK inhibitors with other therapies, such as JAK inhibitors or chemotherapy, to improve outcomes and reduce resistance in conditions like cancer. These trials represent growing interest in the clinical potential of SYK inhibition from a global perspective, spread across North America, Europe, and Asia. The section thus serves as an invaluable resource for stakeholders by providing key insights into the therapeutic potential and geographic spread of these inhibitors.

Leading Companies Engaged In R&D Of SYK Inhibitors

A growing number of pharmaceutical companies and biotech firms are actively involved in the research and development of SYK inhibitors. Rigel Pharmaceuticals, with its marketed product fostamatinib, remains a key player, but other companies are also making strides in this field. Hutchmed's Sovleplenib (HMPL-523), currently progressing through late-stage trials, represents one of the most promising candidates in the pipeline, particularly for ITP. This drug has already received Breakthrough Therapy designation, further underlining its potential to address significant unmet needs in immune thrombocytopenia.

Other companies involved in SYK inhibitor development include major pharma players such as Gilead Sciences and smaller biotech firms such as Ignota Labs and Arcus Biosciences. These companies are targeting a variety of indications, ranging from autoimmune diseases to cancer. Many of these drugs are being tested in combination regimens in an effort to improve response rates and beat back challenges, such as treatment resistance. As the competitive landscape for SYK inhibitors continues to grow, collaboration and licensing agreements are becoming increasingly used as a means of advancing clinical research while accelerating the path to market.

Report Indicating Future Direction Of SYK TIGIT Inhibitors Segment

The segment of SYK inhibitors will see more significant growth in the future with more drugs entering the clinical pipeline and new indications being explored. With the first SYK inhibitor, fostamatinib, already approved for ITP, the therapeutic class is gaining acceptance, and its potential is being further recognized in oncology and autoimmune disease management. The ability of SYK inhibitors to target critical immune cell pathways positions them as an attractive option for diseases with limited treatment options such as chronic lymphocytic leukemia and rheumatoid arthritis.

With new clinical data continuing to emerge, combinations of SYK inhibitors with other immunotherapies, such as PD-1/PD-L1 inhibitors, or with conventional chemotherapy may unlock even greater therapeutic potential. Moreover, research into biomarkers predictive of response to SYK inhibition could enable personalized treatments. This trend is expected to give rise to the development of next-generation SYK inhibitors that could become cornerstones for treating autoimmune and hematologic disorders and even oncology. The market for SYK inhibitors is expected to grow rapidly, with regulatory bodies such as the FDA and EMA offering priority reviews to certain candidates. Further into the future, as trials progress along with the approval of new drugs, the impact of SYK inhibitors on patient care and the broader landscape will continue to increase, bringing hope to patients and opportunities to stakeholders in healthcare and the biopharmaceutical industry.

1. Introduction To Spleen Tyrosine Kinase (SYK)

1.1 Overview of SYK Protein
1.2 SYK Signaling Pathways & Immune Regulation
1.3 Potential Of SYK As Drug Target

2. SYK Inhibitors - Mechanism Of Action

3. SYK Inhibitors Development & Clinical Trends By Indication

3.1 Autoimmune & Inflammatory Diseases
3.2 Cancer
3.3 Microbial Infections
3.4 Eye Diseases

4. Tavalisse - 1st Approved SYK Inhibitor

4.1 Overview & Patent Analysis
4.2 Pricing & Dosage Analysis
4.3 Sales Analysis

5. Global SYK Inhibitors Market Analysis

5.1 Current Market Scenario
5.2 Future Market Outlook

6. SYK Inhibitors Regional Market Analysis

6.1 US
6.2 China
6.3 Europe

7. Global SYK Inhibitors Clinical Pipeline Overview

7.1 By Country
7.2 By Indication
7.3 By Organization
7.4 By Phase

8. Global SYK Inhibitors Clinical Pipeline By Company, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase III
8.7 Preregistration

9. Marketed SYK Inhibitor Clinical & Patent Insight

10. Global SYK Inhibitors Market Dynamics

10.1 Market Drivers & Opportunities
10.2 Market Restraints & Solutions

11. Competitive Landscape

11.1 Aptose Biosciences
11.2 CrystalGenomics
11.3 CSPC Ouyi Pharmaceutical
11.4 Formation Bio
11.5 Genosco
11.6 Hanmi Pharmaceutical
11.7 HUTCHMED
11.8 IACTA Pharmaceuticals
11.9 Ignota Labs
11.10 Rigel Pharmaceuticals

簡介目錄圖表

List of Figures

Figure 1-1: SYK Signaling In Immune & Non-Immune Cells
Figure 1-2: Biological & Pathological Effects Of SYK Activation
Figure 1-3: SYK: Key Discoveries & Milestones
Figure 1-4: SYK Domain Architecture
Figure 1-5: SYK Activation Mechanism
Figure 1-6: SYK - Multi-Disease Therapeutic Relevance
Figure 2-1: SYK Inhibition Mechanism
Figure 2-2: Mechanism Of Action Of SYK Inhibitors On Immune Signaling
Figure 3-1: SYK In Autoimmune & Inflammatory Diseases
Figure 3-2: Fostamatinib In ITP - Mode Of Action
Figure 3-3: C-935788-058 Phase 3 (NCT04138927) Study - Initiation & Completion Year
Figure 3-4: ESLIM-02 Phase 2/3 (NCT05535933) Study - Initiation & Completion Year
Figure 3-5: Pro00113327 Phase 1 (NCT06233110) Study - Initiation & Completion Year
Figure 3-6: Autoimmune & Inflammatory Diseases - SYK Inhibition Effects
Figure 3-7: SYK - Dual Role In Cancer
Figure 3-8: 810834 Phase 1 (NCT06639724) Study - Initiation & Completion Year
Figure 3-9: HM-FLTI-101 Phase 1/2 (NCT03850574) Study - Initiation & Completion Year
Figure 3-10: SYK - Mechanism In Immune Response To Pathogens
Figure 4-1: Fostamatinib - Approval Year By Country/Region
Figure 4-2: US - Price Per Unit & Supply (US$), November'2025
Figure 4-3: Europe - Price Per Unit & Supply (US$), November'2025
Figure 4-4: UK - Price Per Unit & Supply (US$), November'2025
Figure 4-5: Tavalisse - Initial & Increased Dose For The Treatment of Chronic Immune Thrombocytopenia (mg)
Figure 4-6: Global - Tavalisse Sales (US$ Million), 2020-2025
Figure 4-7: Global - Tavalisse Sales (US$ Million), Q1-Q3'2025
Figure 4-8: Global - Tavalisse Sales (US$ Million), Q1-Q4'2024
Figure 5-1: Global - SYK Inhibitors Sales (US$ Million), 2020-2025
Figure 5-2: Global - SYK Inhibitors Market Value (US$ Million), Q1-Q3'2025
Figure 5-3: Global - SYK Inhibitors Market Forecast (US$ Million), 2026 -2030
Figure 5-4: Global SYK Inhibitors Market - Future Opportunities
Figure 7-1: Global - Number Of SYK Inhibitors Clinical Trials By Country, 2025 Till 2030
Figure 7-2: Global - Number Of SYK Inhibitors Clinical Trials By Indication, 2025 Till 2030
Figure 7-3: Global - Number Of SYK Inhibitors Clinical Trials By Organization, 2025 Till 2030
Figure 7-4: Global - Number Of SYK Inhibitors Clinical Trials By Phase, 2025 Till 2030
Figure 10-1: Global SYK Inhibitors Market - Drivers & Opportunities

List of Tables

Table 1-1: SYK - Biological Role In Major Disease Areas
Table 3-1: SYK Inhibition In Microbial Infection - Potential Benefits
Table 3-2: SYK Inhibition In Ocular Disease Management
Table 4-1: Tavalisse - Dose Reduction Schedule
Table 4-2: Tavalisse - Recommended Dose Modifications & Management For Specific Adverse Reactions
Table 10-1: Global SYK Inhibitors Market - Restraints & Solutions

02-2729-4219

+886-2-2729-4219